Total amount raised
$205 Millions
Latest funding date
01/01/2023
Location
Asimov has successfully raised $200 million in its latest funding round, advancing its mission to revolutionize therapeutics design and manufacturing through synthetic biology. The company integrates mammalian synthetic biology, computer-aided design, and machine learning to create tools for programming living cells.
With backing from top investors, Asimov continues to innovate in the fields of biologics, cell therapies, and gene therapies. Keep reading to explore the intricacies of Asimov's fundraising journey and the investors supporting this cutting-edge platform.
What Is Asimov?
Asimov, founded in 2017, is a pioneering company in synthetic biology and biotechnology. Based in Boston, Massachusetts, the company was established by Alec Nielsen, Christopher Voigt, Douglas Densmore, and Raja Srinivas. Asimov employs a multidisciplinary approach, integrating mammalian synthetic biology, computer-aided design, and machine learning to create tools for programming living cells.
With a team of 51-100 employees, Asimov focuses on the design and manufacture of advanced therapeutics, including biologics, cell therapies, and gene therapies. Their end-to-end platform combines engineered host cells, a genetic parts library, and design software, enabling the development of next-generation therapeutics.
How Much Funding Has Asimov Raised?
- Seed Round
- Amount Raised: $5M
- Date: December 2017
- Lead Investors: Andreessen Horowitz
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop foundational technologies and platform for synthetic biology tools.
- Series A
- Amount Raised: $25M
- Date: January 2020
- Lead Investors: Horizons Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance the development of their genetic design platform and expand their product offerings.
- Series B
- Amount Raised: $175M
- Date: January 2023
- Lead Investors: CPP Investments
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale Asimov's tools and services in biologics, cell/gene therapies, and RNA.
Total Amount Raised: $205M
Current Valuation: Not publicly disclosed
Key Investors
- CPP Investments
- Details: CPP Investments, also known as the Canada Pension Plan Investment Board, is a professional investment management organization that invests the funds of the Canada Pension Plan. It is one of the largest pension funds in the world.
- Investment Focus Areas: Health care, infrastructure, real estate, private equity.
- Notable Investments: Asimov, Envision Healthcare, GlobalLogic.
- Horizons Ventures
- Details: Horizons Ventures is a venture capital firm based in Hong Kong, known for investing in disruptive and innovative technology companies. It is the private investment arm of Li Ka-shing.
- Investment Focus Areas: Biotechnology, artificial intelligence, fintech, telecommunications.
- Notable Investments: Asimov, Facebook, Spotify.
- Andreessen Horowitz
- Details: Andreessen Horowitz, also known as a16z, is a private venture capital firm based in Silicon Valley. It was founded by Marc Andreessen and Ben Horowitz.
- Investment Focus Areas: Technology, biotech, consumer, enterprise software.
- Notable Investments: Asimov, Airbnb, Coinbase.
- Fidelity Management & Research Company
- Details: Fidelity Management & Research Company is the investment advisor for Fidelity's family of mutual funds. It is one of the largest asset managers in the world.
- Investment Focus Areas: High-growth potential companies, technology, healthcare.
- Notable Investments: Asimov, Uber, SpaceX.
- Casdin Capital
- Details: Casdin Capital is a New York-based investment firm focused on life sciences and healthcare innovation. It was founded by Eli Casdin.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Asimov, 10x Genomics, Relay Therapeutics.
What's Next for Asimov?
Asimov's future is brimming with opportunities, driven by its recent $200 million funding. The company is poised to scale its platform business, expand R&D, and grow its team. With partnerships with over 25 companies and a contract with DARPA, Asimov is set to revolutionize the field of synthetic biology.
Future fundraising opportunities are likely as Asimov continues to innovate and expand. The integration of AI and machine learning in genetic design presents a significant growth avenue. However, challenges such as high manufacturing costs and ensuring drug quality remain. Asimov's ability to navigate these hurdles will be crucial for its sustained success.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Asimov and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
